Telbivudine
(Redirected from Sebivo)
Telbivudine is an antiviral drug used in the treatment of hepatitis B. It is a synthetic thymidine nucleoside analogue with potent and selective activity against the hepatitis B virus (HBV). Telbivudine is marketed under the brand name Tyzeka in the United States and Sebivo in other countries.
Mechanism of Action[edit | edit source]
Telbivudine works by inhibiting the DNA polymerase of the hepatitis B virus, which is essential for viral replication. By incorporating itself into the viral DNA, telbivudine causes premature chain termination, thereby preventing the virus from multiplying and spreading.
Pharmacokinetics[edit | edit source]
Telbivudine is administered orally and is well absorbed from the gastrointestinal tract. It reaches peak plasma concentrations within 1 to 4 hours after ingestion. The drug is primarily excreted unchanged in the urine, with a half-life of approximately 15 hours.
Clinical Use[edit | edit source]
Telbivudine is indicated for the treatment of chronic hepatitis B in patients with evidence of active viral replication and either evidence of persistent elevations in serum alanine aminotransferase (ALT) or histologically active disease. It is particularly effective in patients who are nucleoside analogue-naive.
Side Effects[edit | edit source]
Common side effects of telbivudine include:
Resistance[edit | edit source]
Resistance to telbivudine can develop, particularly with long-term use. The most common mutation associated with resistance is the M204I mutation in the HBV polymerase gene. Cross-resistance with other nucleoside analogues, such as lamivudine and entecavir, can also occur.
Contraindications[edit | edit source]
Telbivudine is contraindicated in patients with a known hypersensitivity to the drug or any of its components. Caution is advised in patients with renal impairment, as dose adjustments may be necessary.
Pregnancy and Lactation[edit | edit source]
Telbivudine is classified as a pregnancy category B drug. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether telbivudine is excreted in human milk; therefore, caution should be exercised when administered to nursing mothers.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD